SAB Biotherapeutics, Inc.SAB Biotherapeutics, Inc.SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc.

No trades
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪183.29 M‬USD
−2.3745USD
‪−34.11 M‬USD
‪1.32 M‬USD
‪34.40 M‬
Beta (1Y)
1.30

About SAB Biotherapeutics, Inc.


CEO
Samuel J. Reich
Website
Headquarters
Miami Beach
Founded
2014
Identifiers
3
ISIN US78397T1117
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Displays a symbol's price movements over previous years to identify recurring trends.